Trial Profile
A Study to Evaluate the Efficacy of Bevacizumab for Treatment of Late Radiation Induced Myelopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Spinal cord disorders
- Focus Therapeutic Use
- 19 Jan 2016 New trial record
- 06 Jan 2016 Results published in the Neurology